1. Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells.
- Author
-
Cao WJ, Wu K, Wang C, and Wan DM
- Subjects
- Antineoplastic Agents pharmacology, Blotting, Western, Cell Line, Tumor, Cell Proliferation drug effects, Cyclin B1 metabolism, Cyclin D1 metabolism, Humans, Janus Kinase 2 antagonists & inhibitors, Janus Kinase 2 metabolism, Leukemia metabolism, Leukemia pathology, Membrane Potential, Mitochondrial drug effects, Mitochondria metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, Reactive Oxygen Species metabolism, STAT3 Transcription Factor metabolism, bcl-2-Associated X Protein metabolism, Apoptosis drug effects, Cell Cycle Checkpoints drug effects, Glucosides pharmacology, Stilbenes pharmacology
- Abstract
Polydatin (PD), a natural precursor of resveratrol, has a variety of biological activities, including anti‑tumor effects. However, the underlying molecular mechanisms of the anti-cancer activity of PD has not been fully elucidated. The present study demonstrated that PD significantly inhibited the proliferation of the MOLT-4 leukemia cell line in a dose‑ and time-dependent manner by using Cell Counting Kit‑8 assay. PD also dose-dependently increased the apoptotic rate and caused cell cycle arrest in S phase in MOLT‑4 cells, as revealed by flow cytometry. In addition, PD dose-dependently decreased the mitochondrial membrane potential and led to the generation of reactive oxygen species in MOLT-4 cells. Western blot analysis revealed that the expression of anti‑apoptotic protein B-cell lymphoma 2 (Bcl-2) was decreased, whereas that of pro‑apoptotic protein Bcl‑2‑associated X was increased by PD. Furthermore, the expression of two cell cycle regulatory proteins, cyclin D1 and cyclin B1, was suppressed by PD. Of note, the pro‑apoptotic and cell cycle‑inhibitory effects of PD were potentiated by Janus kinase 2 (JAK2) inhibition. In conclusion, the results of the present study strongly suggested that PD is a promising therapeutic compound for the treatment of leukemia, particularly in combination with JAK inhibitors.
- Published
- 2016
- Full Text
- View/download PDF